Day 2 at the FDA: Semax and Epitalon Clear the Panel, DSIP Falls
Day one of the July 2026 PCAC meeting belonged to the famous names — BPC-157, TB-500 — and produced four identical-feeling narrow approvals. Day two, July 24, was where the pattern got interesting: the committee recommended Semax and Epitalon, then broke its streak by rejecting DSIP. For the cognitive and longevity research communities, day two was arguably the bigger story.
Semax: The Cognitive Peptide Clears, 8–5
Semax, a heptapeptide developed in Russia and used clinically there for decades, was reported to pass 8–5 with one abstention. The uses the FDA evaluated were strictly neurological — cerebral ischemia, migraine, and trigeminal neuralgia — a notable mismatch with the compound's actual fame in the US, where it circulates almost entirely as a nootropic for focus and cognitive performance.
That mismatch matters for interpretation. If Semax eventually reaches the 503A list, prescriptions would presumably be written against the evaluated clinical uses, not "I want sharper mornings." The US-language clinical literature is thin; most supporting data is Russian, which FDA staff weighted accordingly in recommending against it. The committee's majority applied the same harm-reduction logic it used all meeting: Semax is already widely used, so a licensed pathway beats the gray market.
Epitalon: The Longevity Community's First Regulatory Win, 7–5
Epitalon, the pineal tetrapeptide central to Russian anti-aging research since the Khavinson era, was reported to pass 7–5 with one abstention. Here too the evaluated use surprises: insomnia — not telomeres, not lifespan. The longevity claims that drive Epitalon's popularity were not before the committee at all.
Still, symbolism counts. Epitalon becoming the first explicitly longevity-associated peptide recommended for a US compounding pathway is a milestone the anti-aging research community will cite for years — even if the citation should honestly read "recommended for insomnia, pending rulemaking, over FDA staff objection."
Reading Day Two as a Whole
| Compound | Reported Vote | Evaluated Use | US Street Reputation |
|---|---|---|---|
| Semax | 8–5, 1 abstention | Cerebral ischemia, migraine, trigeminal neuralgia | Focus / nootropic |
| Epitalon | 7–5, 1 abstention | Insomnia | Longevity / telomere |
| Emideltide (DSIP) | 6–7, 1 abstention — rejected | Opioid withdrawal, insomnia, narcolepsy | Deep sleep |
Day 2 tallies transcribed from the live webcast; the official FDA transcript is pending.
The day-two pattern suggests the committee was not rubber-stamping: it distinguished between compounds with at least some modern clinical footprint (Semax's Russian stroke literature, Epitalon's ongoing research interest) and one whose evidence base is both old and contradicted (DSIP). Whether you find those distinctions persuasive or arbitrary, they were distinctions — the panel drew a line somewhere.
What Happens to Semax and Epitalon Now
Both enter the same queue as the day-one winners: FDA review, then — possibly — notice-and-comment rulemaking running 12–24 months, with the glutathione precedent (recommended 2022, still unlisted) hanging over every estimate. Neither is legal to compound today, and neither moved closer to FDA approval, which is a separate and far taller mountain. Research-grade supply is unchanged. Our profiles cover the underlying science: Semax and Epitalon.
Third-party tested research peptides with published COAs. Use code POWER at checkout.
Code: POWERView Catalog →We may earn a commission from links above at no cost to you. All compounds are for laboratory research use only.
Frequently Asked Questions
On July 24, 2026, the committee recommended Semax (reported 8-5, one abstention) and Epitalon (reported 7-5, one abstention), and rejected emideltide/DSIP by a single vote (6-7, one abstention).
Cerebral ischemia, migraine, and trigeminal neuralgia - not the cognitive-enhancement use it is known for in the US market.
Insomnia. The longevity and telomere claims associated with Epitalon were not part of the FDA's evaluation.
No. Both await FDA review and potential rulemaking, expected to take 12 to 24 months if the agency proceeds at all.
Day-two tallies were transcribed from the live webcast and vote-board records. The official FDA transcript had not been published at the time of writing.